Effectiveness of Adjunctive Antidepressant Treatment

New England Journal of Medicine 356, 1711-1722

DOI: 10.1056/nejmoa064135

Citation Report

#	Article	IF	CITATIONS
1	Mood stabilisers in the treatment of Bipolar II Disorder. , 2008, , 120-132.		3
2	Adjunctive Antidepressant Use and Symptomatic Recovery Among Bipolar Depressed Patients With Concomitant Manic Symptoms: Findings From the STEP-BD. American Journal of Psychiatry, 2007, 164, 1348-1355.	7.2	185
3	Differentiating Bipolar Disorders from Major Depressive Disorders: Treatment Implications. Annals of Clinical Psychiatry, 2007, 19, 305-312.	0.6	30
4	Do effectiveness studies tell us the real truth?. World Journal of Biological Psychiatry, 2007, 8, 138-140.	2.6	3
5	Treatment of Bipolar Depression. New England Journal of Medicine, 2007, 356, 1771-1773.	27.0	23
6	Modafinil Add-On in the Treatment of Bipolar Depression. American Journal of Psychiatry, 2007, 164, 1143-1145.	7.2	6
7	Approaching the Challenge of Bipolar Depression: Results From STEP-BD. American Journal of Psychiatry, 2007, 164, 1301-1303.	7.2	12
8	Intensive Psychosocial Intervention Enhances Functioning in Patients With Bipolar Depression: Results From a 9-Month Randomized Controlled Trial. American Journal of Psychiatry, 2007, 164, 1340-1347.	7.2	238
9	Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine, 2007, 357, 614-616.	27.0	3
10	The Rise and Fall of Mood Stabilizers. Australian and New Zealand Journal of Psychiatry, 2007, 41, 779-783.	2.3	11
11	A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression. American Journal of Psychiatry, 2007, 164, 1242-1249.	7.2	224
12	Psychotropic Medication Use in Older People. Journal of Pharmacy Practice and Research, 2007, 37, 153-156.	0.8	2
13	Bipolar disorder pharmacotherapy. Future Neurology, 2007, 2, 441-450.	0.5	0
14	Unlike lithium, anticonvulsants and antidepressants do not alter rat brain myo-inositol. NeuroReport, 2007, 18, 1595-1598.	1.2	6
15	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology, 2007, 10, S1-207.	2.1	55
17	Bipolar II Disorder. CNS Drugs, 2007, 21, 727-740.	5.9	103
18	Bipolar Spectrum Disorder: Differential Diagnosis and Treatment. Primary Care - Clinics in Office Practice, 2007, 34, 521-550.	1.6	8
19	Is Psychosocial Management Effective?. Archives of General Psychiatry, 2007, 64, 1451.	12.3	O

#	Article	IF	CITATIONS
20	Case Studies in Bipolar Depression: Best Practices for the Outpatient. CNS Spectrums, 2007, 12, 4-13.	1.2	0
21	Is Psychosocial Management Effective?â€"Reply. Archives of General Psychiatry, 2007, 64, 1452.	12.3	0
22	Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Annals of General Psychiatry, 2007, 6, 27.	2.7	56
23	Treatment of refractory bipolar depression. Current Psychiatry Reports, 2007, 9, 495-496.	4.5	1
24	STEP-BD and bipolar depression: What have we learned?. Current Psychiatry Reports, 2007, 9, 497-503.	4.5	50
25	Chronic Administration of Lamotrigine Downregulates COX-2 mRNA and Protein in Rat Frontal Cortex. Neurochemical Research, 2008, 33, 861-866.	3.3	37
26	Bipolar disorder and suicide: Research synthesis and clinical translation. Current Psychiatry Reports, 2008, 10, 66-72.	4.5	75
27	Adjunctive use of modafinil in bipolar patients: just another stimulant or not?. Current Psychiatry Reports, 2008, 10, 520-524.	4.5	10
28	Pharmacotherapy in mania and depression. Annals of General Psychiatry, 2008, 7, .	2.7	0
29	Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a doubleâ€blind, randomized, placeboâ€controlled study. Human Psychopharmacology, 2008, 23, 87-94.	1.5	255
30	Implementing clinical guidelines for bipolar disorder. Psychology and Psychotherapy: Theory, Research and Practice, 2008, 81, 437-458.	2.5	23
31	Bipolar disorder: candidate drug targets. Mount Sinai Journal of Medicine, 2008, 75, 226-247.	1.9	43
32	Antidepressants in bipolar depression. Acta Psychiatrica Scandinavica, 2008, 118, 335-336.	4.5	35
33	Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatrica Scandinavica, 2008, 118, 337-346.	4.5	112
34	Longâ€ŧerm antidepressant treatment in bipolar disorder: metaâ€analyses of benefits and risks. Acta Psychiatrica Scandinavica, 2008, 118, 347-356.	4.5	155
35	Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disorders, 2008, 10, 163-178.	1.9	172
36	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disorders, 2008, 10, 566-579.	1.9	40
37	The modern pharmacopoeia: a return to depressive realism?. Bipolar Disorders, 2008, 10, 969-972.	1.9	5

#	Article	IF	Citations
38	Treatmentâ€emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disorders, 2008, 10, 907-915.	1.9	40
39	Why antidepressants are not antidepressants: STEPâ€BD, STAR*D, and the return of neurotic depression. Bipolar Disorders, 2008, 10, 957-968.	1.9	124
40	Upping the ante on antidepressants. Bipolar Disorders, 2008, 10, 975-978.	1.9	4
41	Prioritizing Future Research on Offâ€Label Prescribing: Results of a Quantitative Evaluation. Pharmacotherapy, 2008, 28, 1443-1452.	2.6	87
42	Treatment of bipolar depression: An update. Journal of Affective Disorders, 2008, 109, 21-34.	4.1	78
43	The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study. Journal of Affective Disorders, 2008, 109, 91-97.	4.1	25
44	A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. Journal of Affective Disorders, 2008, 110, 70-74.	4.1	38
45	Antidepressant utilisation patterns and determinants of short-term and non-psychiatric use in the Finnish general adult population. Journal of Affective Disorders, 2008, 110, 94-105.	4.1	70
46	Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. Journal of Affective Disorders, 2008, 111, 372-377.	4.1	64
47	Effectiveness of lamotrigine in bipolar disorder in a clinical setting. Journal of Psychiatric Research, 2008, 43, 13-23.	3.1	21
48	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial. Biological Psychiatry, 2008, 64, 468-475.	1.3	452
49	Pharmacotherapy of Mood Disorders. Annual Review of Clinical Psychology, 2008, 4, 53-91.	12.3	65
50	The broad clinical spectrum of bipolar disorder: implications for research and practice. Journal of Psychopharmacology, 2008, 22, 397-400.	4.0	21
51	A tetrachoric factor analysis validation of mixed depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 186-192.	4.8	17
52	S.25.03 Use of antidepressants in long treatment of bipolar depression. European Neuropsychopharmacology, 2008, 18, S192-S193.	0.7	0
54	S.25.05 Atypical antipsychotics in bipolar depression: a new major option?. European Neuropsychopharmacology, 2008, 18, S193.	0.7	0
55	ECNP consensus meeting. Bipolar depression. Nice, March 2007. European Neuropsychopharmacology, 2008, 18, 535-549.	0.7	131
56	Case 24-2008. New England Journal of Medicine, 2008, 359, 509-515.	27.0	9

#	Article	IF	CITATIONS
57	Overcoming the current approach in bipolar disorder research: towards DSM-V and beyond. Journal of Psychopharmacology, 2008, 22, 406-407.	4.0	5
58	Bupropion extended-release for depressive disorders. Expert Review of Neurotherapeutics, 2008, 8, 715-722.	2.8	13
59	The broad spectrum of bipolar disorder: implications for research and practice — a commentary. Journal of Psychopharmacology, 2008, 22, 401-401.	4.0	0
60	N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. Neuropsychopharmacology, 2008, 33, 2303-2312.	5.4	282
61	Mood lability and bipolar disorder in children and adolescents. International Review of Psychiatry, 2008, 20, 171-176.	2.8	5
62	Antidepressants in the Treatment of Bipolar Disorder: Decoding Contradictory Evidence and Opinion. Harvard Review of Psychiatry, 2008, 16, 205-209.	2.1	7
63	On being bipolar without being bipolar. Journal of Psychopharmacology, 2008, 22, 402-403.	4.0	0
64	Progress in Neurotherapeutics and Neuropsychopharmacology 2008. Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	0
66	Treatment of Rapid-Cycling Bipolar Disorder: Are Antidepressants Mood Destabilizers?. American Journal of Psychiatry, 2008, 165, 300-302.	7.2	54
67	Antidepressant Prescribing and Rapid Cycling. American Journal of Psychiatry, 2008, 165, 1048-1049.	7.2	3
68	Dr. Schneck and Colleagues Reply. American Journal of Psychiatry, 2008, 165, 1049-1049.	7.2	0
69	Bringing a research base to psychiatry. Cmaj, 2008, 178, 1257-1258.	2.0	1
70	Mixed Depression and Rapid Cycling. American Journal of Psychiatry, 2008, 165, 1048-1048.	7.2	3
71	Etablir une base de recherche en psychiatrie. Cmaj, 2008, 178, 1259-1260.	2.0	0
72	Switching, Induction of Rapid Cycling, and Increased Suicidality With Antidepressants in Bipolar Patients: <i>Fact or Overinterpretation?</i> CNS Spectrums, 2008, 13, 790-795.	1.2	53
73	Pharmacotherapy for Bipolar Depression: A Review of the Evidence. Current Psychiatry Reviews, 2008, 4, 145-156.	0.9	3
74	The Contemporary Face of Bipolar Illness: <i>Complex Diagnostic and Therapeutic Challenges</i> Complex Spectrums, 2008, 13, 763-779.	1.2	16
75	Quetiapine monotherapy for bipolar depression. Neuropsychiatric Disease and Treatment, 0, , 21.	2.2	10

#	Article	IF	CITATIONS
76	Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder. Neuropsychiatric Disease and Treatment, 2008, 4, 311.	2.2	29
77	Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. Neuropsychiatric Disease and Treatment, 2007, Volume 3, 847-853.	2.2	8
78	Adequacy of Pharmacotherapy Among Medicaid-Enrolled Patients Newly Diagnosed with Obsessive-Compulsive Disorder. CNS Spectrums, 2009, 14, 695-703.	1.2	5
80	Effectiveness as an outcome measure for treatment trials in psychiatry. World Psychiatry, 2009, 8, 23-27.	10.4	17
81	Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2009, 23, 346-388.	4.0	451
82	Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 2009, 194, 4-9.	2.8	370
83	Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy. , 2009, , .		5
84	Recent advances in bipolar disorder pharmacotherapy: focus on bipolar depression and rapid cycling. Expert Review of Clinical Pharmacology, 2009, 2, 423-434.	3.1	3
85	Antidepressant-Induced Mania with Concomitant Mood Stabilizer in Patients with Comorbid Substance Abuse and Bipolar Disorder. Journal of Addictive Diseases, 2009, 28, 348-355.	1.3	9
86	Evaluation of Treatment in 35 Cases of Bipolar Suicide. Australian and New Zealand Journal of Psychiatry, 2009, 43, 503-508.	2.3	45
87	Meta-Analysis of Antidepressant Augmentation: Piling on in the Absence of Evidence. Ethical Human Psychology and Psychiatry, 2009, 11, 171-182.	0.5	4
88	Where should bipolar disorder appear in the meta-structure?. Psychological Medicine, 2009, 39, 2071-2081.	4.5	43
89	Antidepressant Treatment and Smoking Cessation in Bipolar Disorder. JAMA - Journal of the American Medical Association, 2009, 301, 2093.	7.4	3
90	National Patterns in Antidepressant Medication Treatment. Archives of General Psychiatry, 2009, 66, 848.	12.3	636
91	Antidepressant-Induced Mood Conversions in Bipolar Disorder: A Retrospective Study of Tricyclic versus Non-Tricyclic Antidepressant Drugs. Neuropsychobiology, 2009, 59, 12-16.	1.9	48
92	Mixed Depression: The Importance of Rediscovering Subtypes of Mixed Mood States. American Journal of Psychiatry, 2009, 166, 127-130.	7.2	19
93	Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression. Psychotherapy and Psychosomatics, 2009, 78, 391-393.	8.8	15
94	Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression. American Journal of Psychiatry, 2009, 166, 164-172.	7.2	161

#	Article	IF	CITATIONS
95	Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. Neuropsychopharmacology, 2009, 34, 204-212.	5.4	16
97	Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD. American Journal of Psychiatry, 2009, 166, 173-181.	7.2	263
98	Treatment-refractory bipolar disorder: classification to aid in clinical management. Expert Opinion on Pharmacotherapy, 2009, 10, 1907-1915.	1.8	19
99	New Hope for Pharmacogenetic Testing. American Journal of Psychiatry, 2009, 166, 635-638.	7.2	2
100	Treatment response and duration of maintenance treatment with adjunctive antidepressants in bipolar depression: A retrospective chart review. International Journal of Psychiatry in Clinical Practice, 2009, 13, 130-137.	2.4	2
101	Improving Mental Health Treatments Through Comparative Effectiveness Research. Health Affairs, 2009, 28, 783-791.	5.2	22
102	Decreased Glutamate/Glutamine Levels May Mediate Cytidine's Efficacy in Treating Bipolar Depression: A Longitudinal Proton Magnetic Resonance Spectroscopy Study. Neuropsychopharmacology, 2009, 34, 1810-1818.	5 . 4	62
103	Treating Childhood Psychopathology and Developmental Disabilities. , 2009, , .		2
104	Safety and Efficacy of Quetiapine in Bipolar Depression. Annals of Pharmacotherapy, 2009, 43, 1848-1856.	1.9	22
105	The supra-additive hyperactivity caused by an amphetamine–chlordiazepoxide mixture exhibits an inverted-U dose response: Negative implications for the use of a model in screening for mood stabilizers. Pharmacology Biochemistry and Behavior, 2009, 92, 649-654.	2.9	24
106	Are guidelines in need of CPR? The development of clinical practice recommendations (CPR). Acta Psychiatrica Scandinavica, 2009, 119, 5-7.	4.5	16
107	Clinical practice recommendations for bipolar disorder. Acta Psychiatrica Scandinavica, 2009, 119, 27-46.	4.5	110
108	Bipolar disorder and mechanisms of action of mood stabilizers. Brain Research Reviews, 2009, 61, 185-209.	9.0	125
109	Differences between subjective and objective assessments of the utility of Electroconvulsive therapy in patients with bipolar and unipolar depression. Journal of Affective Disorders, 2009, 112, 212-218.	4.1	31
110	Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: A randomized, parallel group, open-label trial. Journal of Affective Disorders, 2009, 112, 219-230.	4.1	52
111	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, 2009, 114, 1-13.	4.1	75
112	Treatment of depressed bipolar patients with alcohol use disorders: Plenty of room for improvement. Journal of Affective Disorders, 2009, 115, 262-268.	4.1	13
113	Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Affective Disorders, 2009, 115, 367-375.	4.1	377

#	Article	IF	CITATIONS
114	Response to ECT in bipolar I, bipolar II and unipolar depression. Journal of Affective Disorders, 2009, 118, 55-59.	4.1	100
115	Ziprasidone monotherapy in bipolar II depression: An open trial. Journal of Affective Disorders, 2009, 118, 205-208.	4.1	25
116	Lessons from STEP-BD for the treatment of bipolar depression. Depression and Anxiety, 2009, 26, 106-109.	4.1	16
117	Antidepressant Adequacy and Work Status Among Medicaid Enrollees with Disabilities: A Restriction-based, Propensity Score-adjusted Analysis. Community Mental Health Journal, 2009, 45, 333-340.	2.0	11
118	Preliminary results of a fineâ€grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective lifeâ€chartâ€methodology. Acta Psychiatrica Scandinavica, 2009, 120, 474-480.	4.5	15
119	Treatmentâ€resistant bipolar depression: towards a new definition. Acta Psychiatrica Scandinavica, 2009, 120, 429-440.	4.5	63
120	Mania associated with antidepressant treatment: comprehensive metaâ€analytic review. Acta Psychiatrica Scandinavica, 2010, 121, 404-414.	4.5	190
121	Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study. Bipolar Disorders, 2009, 11, 89-94.	1.9	47
122	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.9	545
123	Ultraâ€brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. Bipolar Disorders, 2009, 11, 418-424.	1.9	81
124	Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disorders, 2009, 11, 34-44.	1.9	98
125	Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disorders, 2009, 11, 55-76.	1.9	43
126	Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disorders, 2009, 11, 84-91.	1.9	26
127	Psychosocial treatments for bipolar disorder: costâ€effectiveness, mediating mechanisms, and future directions. Bipolar Disorders, 2009, 11, 110-122.	1.9	156
128	Suicidal ideation and depressive symptoms among bipolar patients as predictors of the health and wellâ€being of caregivers. Bipolar Disorders, 2009, 11, 876-884.	1.9	23
129	A commentary on "Sleep disturbance in bipolar disorder.". Clinical Psychology: Science and Practice, 2009, 16, 278-280.	0.9	1
130	Rapid and Sustained Antidepressant Response with Sleep Deprivation and Chronotherapy in Bipolar Disorder. Biological Psychiatry, 2009, 66, 298-301.	1.3	220
131	Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression. Journal of Clinical Psychiatry, 2009, 70, 223-231.	2.2	200

#	Article	IF	CITATIONS
132	Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. World Journal of Biological Psychiatry, 2009, 10, 6-26.	2.6	80
133	Neurocognitive Mechanisms in Depression: Implications for Treatment. Annual Review of Neuroscience, 2009, 32, 57-74.	10.7	386
134	Revised Korean medication algorithm for bipolar disorder. World Journal of Biological Psychiatry, 2009, 10, 846-855.	2.6	22
135	The primacy of mania: A reconsideration of mood disorders. European Psychiatry, 2009, 24, 125-134.	0.2	53
136	Antidepressants are not all created equal. Lancet, The, 2009, 373, 700-701.	13.7	11
137	Polysomnographic Features of Medical and Psychiatric Disorders and Their Treatments. Sleep Medicine Clinics, 2009, 4, 407-419.	2.6	4
138	An update on the treatment of bipolar depression. Expert Opinion on Pharmacotherapy, 2009, 10, 161-172.	1.8	13
139	Effectiveness and Safety of the Combination of Fluoxetine and Olanzapine in Outpatients With Bipolar Depression. Journal of Clinical Psychopharmacology, 2009, 29, 358-361.	1.4	29
140	Recent progress in the pharmacotherapy of bipolar disorder. Future Neurology, 2009, 4, 493-508.	0.5	0
141	Recent advances in the biological treatment of mood disorders. Irish Journal of Psychological Medicine, 2009, 26, i-ix.	1.0	2
142	Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States. Psychiatric Services, 2009, 60, 601-610.	2.0	34
143	Lamotrigine-associated rash: to rechallenge or not to rechallenge?. International Journal of Neuropsychopharmacology, 2009, 12, 257.	2.1	26
144	Dr. Goldberg Replies. American Journal of Psychiatry, 2009, 166, 830-831.	7.2	0
145	Managing Sleep Disturbance in Bipolar Disorder. Current Psychiatry Reviews, 2009, 5, 194-201.	0.9	6
146	Is Monotherapy as Good as Polypharmacy in Longâ€"Term Treatment of Bipolar Disorder?. Canadian Journal of Psychiatry, 2009, 54, 719-725.	1.9	16
147	Co-occurring Conditions and Health-Related Quality of Life in Patients With Bipolar Disorder. Psychosomatic Medicine, 2009, 71, 894-900.	2.0	25
148	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. International Clinical Psychopharmacology, 2010, 25, 297-301.	1.7	18
149	Assessing the Relationship Between Compliance With Antidepressant Therapy and Employer Costs Among Employees in the United States. Journal of Occupational and Environmental Medicine, 2010, 52, 115-124.	1.7	14

#	ARTICLE	IF	CITATIONS
150	Efficacy and Mood Conversion Rate of Short-Term Fluoxetine Monotherapy of Bipolar II Major Depressive Episode. Journal of Clinical Psychopharmacology, 2010, 30, 306-311.	1.4	44
151	Treatment Options for Bipolar Depression. Journal of Clinical Psychopharmacology, 2010, 30, 579-590.	1.4	101
152	The course of bipolar disorder. Advances in Psychiatric Treatment, 2010, 16, 318-328.	0.5	47
158	Prevalence and Impact of Manic Traits in Depressed Patients Initiating Interferon Therapy for Chronic Hepatitis C Infection. Journal of Clinical Gastroenterology, 2010, 44, e141-e146.	2.2	12
159	Reply to Goldberg Letter. American Journal of Psychiatry, 2010, 167, 869-869.	7.2	1
160	Advancing Bipolar Disorder: Key Lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Canadian Journal of Psychiatry, 2010, 55, 136-143.	1.9	34
161	Bipolar Depression: Overview and Commentary. Harvard Review of Psychiatry, 2010, 18, 143-157.	2.1	128
163	Polish version of the Hypomania Checklist (HCL-32) scale: the results in treatment-resistant depression. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 139-144.	3.2	33
164	An Overview of Mood Disorders in the DSM-5. Current Psychiatry Reports, 2010, 12, 531-538.	4.5	23
165	Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms. Current Psychiatry Reports, 2010, 12, 512-521.	4.5	20
166	Long-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review. Psychiatric Quarterly, 2010, 81, 207-213.	2.1	15
167	Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. Journal of Psychiatric Research, 2010, 44, 921-929.	3.1	8
168	Maintenance treatment received by patients with bipolar I and II disorders $\hat{a} \in \text{``A naturalistic prospective study. Journal of Affective Disorders, 2010, 121, 116-126.}$	4.1	12
169	Divalproex extended-release in acute bipolar II depression. Journal of Affective Disorders, 2010, 124, 170-173.	4.1	13
170	Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis. Journal of Affective Disorders, 2010, 124, 228-234.	4.1	106
171	Reducing the Hypomania Checklist (HCL-32) to a 16-item version. Journal of Affective Disorders, 2010, 124, 351-356.	4.1	39
172	Manic symptoms in patients with depressive and/or anxiety disorders. Journal of Affective Disorders, 2010, 126, 252-256.	4.1	11
173	Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?. Journal of Affective Disorders, 2010, 127, 10-18.	4.1	77

#	Article	IF	Citations
174	Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8â€week open label trial. Human Psychopharmacology, 2010, 25, 30-36.	1.5	13
175	Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placeboâ€controlled pilot study. Human Psychopharmacology, 2010, 25, 126-132.	1.5	33
176	The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry, 2010, 10, 16.	2.6	23
177	Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatrica Scandinavica, 2010, 121, 201-208.	4.5	33
178	Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatrica Scandinavica, 2010, 122, 246-254.	4.5	33
179	Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry and Clinical Neurosciences, 2010, 64, 367-371.	1.8	11
180	The king is dead, long live the king! The restoration of BALANCE. Bipolar Disorders, 2010, 12, 681-684.	1.9	11
181	The common adolescent bipolar phenotype shows positive biases in emotional processing. Bipolar Disorders, 2010, 12, 606-615.	1.9	25
182	Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disorders, 2010, 12, 691-701.	1.9	24
183	Something Borrowed, Something Blue:Why is Bipolar Disorder an Orphan?. CNS Spectrums, 2010, 15, 15-16.	1.2	0
184	Pharmacologic Treatment of Bipolar Disorder. CNS Spectrums, 2010, 15, 10-13.	1.2	0
185	Practical treatment guidelines for management of bipolar disorder., 0,, 33-43.		1
186	The pharmacological treatment of bipolar disorder in primary care. Medical Journal of Australia, 2010, 193, S24-30.	1.7	9
188	Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S1945.	0.4	1
189	A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Archives of General Psychiatry, 2010, 67, 793.	12.3	848
190	Comparative Response to Electroconvulsive Therapy in Medication-Resistant Bipolar I Patients With Depression and Mixed State. Journal of ECT, 2010, 26, 82-86.	0.6	38
191	The New Lithium Clinic. Neuropsychobiology, 2010, 62, 17-26.	1.9	16
192	Lithium in bipolar and other affective disorders: prescribing practice in the UK. Journal of Psychopharmacology, 2010, 24, 1739-1746.	4.0	34

#	Article	IF	CITATIONS
193	N- methyl-D-aspartate Glutamate Receptor Antagonists and the Promise of Rapid-Acting Antidepressants. Archives of General Psychiatry, 2010, 67, 1110.	12.3	34
194	The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances. Harvard Review of Psychiatry, 2010, 18, 266-278.	2.1	23
195	Efficacy and Safety of Long-Term Fluoxetine Versus Lithium Monotherapy of Bipolar II Disorder: A Randomized, Double-Blind, Placebo-Substitution Study. American Journal of Psychiatry, 2010, 167, 792-800.	7.2	133
196	Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. British Journal of Psychiatry, 2010, 196, 266-273.	2.8	42
197	Bipolar Disorder: An Update. Postgraduate Medicine, 2010, 122, 24-31.	2.0	14
198	Psychotropic drug safety issues: continuing vigilance is needed. Expert Review of Clinical Pharmacology, 2010, 3, 427-432.	3.1	0
199	Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 2010, 13, 813-832.	2.1	42
200	The Psychopharmacology Algorithm Project at the Harvard South Shore Program. Harvard Review of Psychiatry, 2010, 18, 36-55.	2.1	16
201	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry, 2010, 11, 81-109.	2.6	322
202	Transition to Mania During Treatment of Bipolar Depression. Neuropsychopharmacology, 2010, 35, 2545-2552.	5.4	72
203	Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region. Biological Psychiatry, 2010, 68, 536-543.	1.3	109
205	Risperidone long-acting injectable (Risperdal Consta $<$ sup $>$ Â $^{\odot}<$ /sup $>$) for maintenance treatment in patients with bipolar disorder. Expert Review of Neurotherapeutics, 2010, 10, 1637-1658.	2.8	41
206	Sleep, illness course, and concurrent symptoms in inter-episode bipolar disorder. Journal of Behavior Therapy and Experimental Psychiatry, 2010, 41, 145-149.	1.2	57
207	A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology, 2010, 63, 142-153.	5.0	132
209	Bipolar spectrum disorders in primary care: optimising diagnosis and treatment. British Journal of General Practice, 2010, 60, 322-324.	1.4	13
214	Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet, The, 2010, 375, 385-395.	13.7	467
215	Neuroprotection in Bipolar Depression. , 2010, , 451-483.		1
216	Subtyping Major Depressive Disorder. Psychotherapy and Psychosomatics, 2010, 79, 131-135.	8.8	103

#	Article	IF	CITATIONS
217	H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study. World Journal of Biological Psychiatry, 2011, 12, 119-126.	2.6	102
218	Broadening the diagnosis of bipolar disorder: benefits vs. risks. World Psychiatry, 2011, 10, 181-186.	10.4	32
219	Psychopharmacological treatment of bipolar disorder in Latin American. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2011, 4, 205-211.	0.3	2
220	Antidepressant Utilization, Adherence, and Health Care Spending in the United States: The Case of MDD Patients 2000-2007. Health Outcomes Research in Medicine, 2011, 2, e79-e89.	0.6	9
221	Bipolare affektive Störungen., 2011, , 1665-1700.		0
222	Bipolar Disorder â€" A Focus on Depression. New England Journal of Medicine, 2011, 364, 51-59.	27.0	141
225	Which psychosocial interventions in bipolar depression ?. L'Encephale, 2011, 37, S214-S217.	0.9	1
226	2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery. European Neuropsychopharmacology, 2011, 21, 287-293.	0.7	60
227	Factors associated with initial treatment response with antidepressants in bipolar disorder. European Neuropsychopharmacology, 2011, 21, 362-369.	0.7	31
228	Pharmacotherapy for the Treatment of Acute Bipolar II Depression. Journal of Clinical Psychiatry, 2011, 72, 356-366.	2.2	54
229	Adult ADHD and mood disorders. , 0, , 121-129.		1
232	Current and Emerging Therapies for the Management of Bipolar Disorders. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S4441.	1.9	9
233	Bupropion-Induced Mania and Hypomania: A Report of Two Cases. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E51-E52.	1.8	11
234	Trajectories of Depression Severity in Clinical Trials of Duloxetine. Archives of General Psychiatry, 2011, 68, 1227.	12.3	106
235	Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. International Clinical Psychopharmacology, 2011, 26, 96-106.	1.7	54
236	Case Report on the Management of Depression in Schizoaffective Disorder, Bipolar Type Focusing on Lithium Levels and Measurement-Based Care. Journal of Nervous and Mental Disease, 2011, 199, 989-990.	1.0	9
237	Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression. Focus (American Psychiatric Publishing), 2011, 9, 540-548.	0.8	1
238	Guidelines for Treatment-Resistant Mania in Children with Bipolar Disorder. Journal of Psychiatric Practice, 2011, 17, 186-193.	0.7	11

#	Article	IF	CITATIONS
239	Unrecognised bipolar disorder in primary care patients with depression. British Journal of Psychiatry, 2011, 199, 49-56.	2.8	127
240	Long-term prospective mood self-rating and antidepressant treatment. Irish Journal of Psychological Medicine, 2011, 28, 227-229.	1.0	1
241	Bipolar and Substance Use Disorder Comorbidity: Diagnostic and Treatment Considerations. Focus (American Psychiatric Publishing), 2011, 9, 428-434.	0.8	3
242	Unipolar and bipolar depression: different or the same?. British Journal of Psychiatry, 2011, 199, 272-274.	2.8	32
243	What's Up with Bipolar Disorder?. Focus (American Psychiatric Publishing), 2011, 9, 415-422.	0.8	2
244	Lithium Plus Valproate Combination Therapy Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE): A Randomised Open-Label Trial. Focus (American Psychiatric Publishing), 2011, 9, 488-499.	0.8	4
245	Ask the Experts: How are we currently dealing with bipolar disorder and what changes are occurring?. Neuropsychiatry, 2011, 1, 533-536.	0.4	0
246	Managing late-life bipolar disorder: an update. Aging Health, 2011, 7, 557-571.	0.3	1
247	Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disorders, 2011, 13, 111-117.	1.9	44
248	Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disorders, 2011, 13, 145-154.	1.9	62
249	Subthreshold bipolarity: diagnostic issues and challenges. Bipolar Disorders, 2011, 13, 587-603.	1.9	82
250	Predictive animal models of mania: hits, misses and future directions. British Journal of Pharmacology, 2011, 164, 1263-1284.	5.4	117
251	Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. Acta Psychiatrica Scandinavica, 2011, 123, 175-189.	4.5	42
252	Treating bipolar depression – antidepressants and alternatives: a critical review of the literature. Acta Neuropsychiatrica, 2011, 23, 94-105.	2.1	9
253	New treatment guidelines for acute bipolar depression: A systematic review. Journal of Affective Disorders, 2011, 129, 14-26.	4.1	135
254	Physical treatments for bipolar disorder: A review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. Journal of Affective Disorders, 2011, 132, 1-13.	4.1	82
255	Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. Journal of Affective Disorders, 2011, 130, 171-179.	4.1	49
256	Differences between bipolar I and bipolar II disorders in clinical features, comorbidity, and family history. Journal of Affective Disorders, 2011, 131, 59-67.	4.1	113

#	Article	IF	CITATIONS
257	Association between cyclothymic temperament and clinical predictors of bipolarity in recurrent depressive patients. Journal of Affective Disorders, 2011, 132, 285-288.	4.1	42
258	Depression and Anxiety in Late Life: Diagnostic Insights and Therapeutic Options. Mount Sinai Journal of Medicine, 2011, 78, 527-545.	1.9	21
259	Managing bipolar depression: a therapeutic challenge?. Progress in Neurology and Psychiatry, 2011, 15, 21-25.	0.9	0
260	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 207-245.	3.2	40
261	Bipolar Depression: An Evidence-Based Approach. Current Psychiatry Reports, 2011, 13, 483-487.	4.5	6
262	Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?. Annals of General Psychiatry, 2011, 10, 8.	2.7	16
263	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depression and Anxiety, 2011, 28, 267-281.	4.1	23
264	Subthreshold Hypomanic Symptoms in Progression From Unipolar Major Depression to Bipolar Disorder. American Journal of Psychiatry, 2011, 168, 40-48.	7.2	178
265	Distinguishing Symptoms of ADHD from Other Psychiatric Disorders in the Adult Primary Care Setting. Postgraduate Medicine, 2011, 123, 88-98.	2.0	10
266	Bipolar Disorder is Common in Depressed Primary Care Patients. Postgraduate Medicine, 2011, 123, 129-133.	2.0	13
267	Bipolar Phenomenology: Have We Learned All We Can Learn?. American Journal of Psychiatry, 2011, 168, 4-6.	7.2	3
268	The continuum of unipolar depression ―bipolar II depression ―bipolar I depression: different treatments indicated?. World Psychiatry, 2011, 10, 196-197.	10.4	2
269	The dilemma in the concept and the management of bipolar disorder. Middle East Current Psychiatry, 2011, 18, 190-194.	1.2	0
270	Bipolar depression: clinically missed, pharmacologically mismanaged. Therapeutic Advances in Psychopharmacology, 2011, 1, 153-162.	2.7	18
271	Management of Bipolar II Disorder. Indian Journal of Psychological Medicine, 2011, 33, 18-28.	1.5	12
272	Bipolar spektrumunun yeniden keÅŸfi. Noropsikiyatri Arsivi, 2011, 48, 1-1.	0.7	0
273	Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode. Archives of General Psychiatry, 2011, 68, 791.	12.3	359
274	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. Focus (American Psychiatric Publishing), 2011, 9, 500-525.	0.8	1

#	Article	IF	CITATIONS
275	Systems of Psychotherapy., 2011,,.		14
276	Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. American Journal of Psychiatry, 2011, 168, 386-394.	7.2	53
277	Management of Bipolar Depression. Indian Journal of Psychological Medicine, 2011, 33, 11-17.	1.5	4
278	Correlates of Treatment Response in Depressed Older Adults With Bipolar Disorder. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 37-42.	2.3	15
279	Antidepressants: The scapegoat of poor outcome bipolar disorder?. Australian and New Zealand Journal of Psychiatry, 2012, 46, 302-305.	2.3	6
280	Revolution Stalled. Science Translational Medicine, 2012, 4, 155cm11.	12.4	207
281	Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression. Journal of Clinical Psychopharmacology, 2012, 32, 470-478.	1.4	53
282	Quetiapine for bipolar depression. International Clinical Psychopharmacology, 2012, 27, 76-90.	1.7	40
283	US Psychiatric Residents' Treatment of Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 231-236.	1.4	12
284	Bipolar Antidepressant Agents: <i>Shaken not stirred</i> Australian and New Zealand Journal of Psychiatry, 2012, 46, 289-292.	2.3	9
285	Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. Journal of Psychopharmacology, 2012, 26, 603-617.	4.0	81
286	Comprehension and companionship in the emergency department as predictors of treatment adherence. Australasian Psychiatry, 2012, 20, 112-116.	0.7	11
287	Antidepressants in bipolar depression: The clinical debate. Australian and New Zealand Journal of Psychiatry, 2012, 46, 298-301.	2.3	19
288	Evaluation of antidepressant choices for the treatment of depressive symptoms in patients with bipolar disorder / İki uçlu bozukluğu olan hastalarda depresif belirtilerin tedavisinde antidepresan tercihlerinin değerlendirilmesi. Dusunen Adam, 2012, , 151-156.	0.2	0
289	Antidepressant Treatment for Acute Bipolar Depression: An Update. Depression Research and Treatment, 2012, 2012, 1-10.	1.3	17
290	Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed. Current Pharmaceutical Design, 2012, 18, 5828-5836.	1.9	4
291	Module 12. Achieving concordance in the treatment of bipolar disorder. NursePrescribing, 2012, 10, 1-7.	0.1	0
292	Exposure to Antidepressant Medications and Suicide Attempts in Adult Depressed Inpatients. Journal of Nervous and Mental Disease, 2012, 200, 531-534.	1.0	4

#	ARTICLE	IF	CITATIONS
293	Review of Transcranial Magnetic Stimulation for Bipolar Disorder. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2012, 47, 25-31.	0.1	3
294	Review of Transcranial Magnetic Stimulation for Bipolar Disorder. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2012, 47, 32.	0.1	0
295	Bipolar depression and treatment with antidepressants. British Journal of Psychiatry, 2012, 200, 5-6.	2.8	44
296	The role of antidepressants in managing Bipolar II disorder. , 0, , 100-113.		O
297	Nearâ€infrared spectroscopy of bipolar disorder may be distinct from that of unipolar depression and of healthy controls. Asia-Pacific Psychiatry, 2012, 4, 258-265.	2.2	3
298	Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEPâ€BD). CNS Neuroscience and Therapeutics, 2012, 18, 243-249.	3.9	63
299	State of the Art: Treatment of Bipolar Disorders. CNS Neuroscience and Therapeutics, 2012, 18, 214-218.	3.9	22
300	Refractoriness in Bipolar Disorder: Definitions and Evidenceâ€Based Treatment. CNS Neuroscience and Therapeutics, 2012, 18, 227-237.	3.9	30
301	Use of the Hypomania Checklist-32 and the Mood Disorder Questionnaire for detecting bipolarity in 1,051 patients with major depressive disorder. European Psychiatry, 2012, 27, 577-581.	0.2	26
302	The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?. Expert Opinion on Pharmacotherapy, 2012, 13, 2037-2051.	1.8	30
303	Awareness changes placebo effects for feeling relaxed, but not for liking. Journal of Marketing Communications, 2012, 18, 379-396.	4.0	3
304	Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Australian and New Zealand Journal of Psychiatry, 2012, 46, 1058-1067.	2.3	82
305	Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development. Neuropsychopharmacology, 2012, 37, 77-101.	5 . 4	105
306	Characteristics of bipolar disorder patients given antidepressants. Human Psychopharmacology, 2012, 27, 486-491.	1.5	14
307	Lamotrigine as addâ€on treatment to lithium and divalproex: lessons learned from a doubleâ€blind, placeboâ€controlled trial in rapidâ€cycling bipolar disorder. Bipolar Disorders, 2012, 14, 780-789.	1.9	29
308	Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. Neuropsychopharmacology, 2012, 37, 1647-1655.	5.4	166
310	An Update on Antidepressant Use in Bipolar Depression. Current Psychiatry Reports, 2012, 14, 696-704.	4. 5	47
311	Are bipolar disorders underdiagnosed in patients with depressive episodes? Results of the multicenter BRIDGE screening study in Germany. Journal of Affective Disorders, 2012, 142, 45-52.	4.1	29

#	Article	IF	CITATIONS
312	New Approaches in the Treatment of Bipolar Depression. Current Topics in Behavioral Neurosciences, 2012, 14, 291-307.	1.7	6
313	Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry, 2012, 12, 153.	2.6	39
314	Evidence-based pharmacotherapy of bipolar disorder., 0,, 39-52.		0
315	Psychiatry and Sleep. , 2012, , 593-613.		4
316	The bipolar spectrum. , 2012, , 10-34.		4
317	Management commentary., 0,, 254-257.		O
318	Pharmacological Treatment of Bipolar Depression: Qualitative Systematic Review of Double-Blind Randomized Clinical Trials. Psychiatric Quarterly, 2012, 83, 161-175.	2.1	4
319	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 1-48.	3.2	113
320	Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of Affective Disorders, 2012, 138, 222-238.	4.1	39
321	Bipolarity and inadequate response to antidepressant drugs: Clinical and psychopharmacological perspective. Journal of Affective Disorders, 2012, 136, e13-e19.	4.1	39
322	Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. Journal of Affective Disorders, 2012, 136, e21-e29.	4.1	36
323	The Affective and Emotional Composite Temperament (AFECT) model and scale: A system-based integrative approach. Journal of Affective Disorders, 2012, 140, 14-37.	4.1	49
324	Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Journal of Affective Disorders, 2012, 136, 534-542.	4.1	49
325	Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. Journal of Affective Disorders, 2012, 137, 139-145.	4.1	3
326	Bipolar depression: Clinical correlates of receiving antidepressants. Journal of Affective Disorders, 2012, 139, 89-93.	4.1	48
327	The change of QEEG prefrontal cordance as a response predictor to antidepressive intervention in bipolar depression. A pilot study. Journal of Psychiatric Research, 2012, 46, 219-225.	3.1	26
328	Genetic approaches to a better understanding of bipolar disorder. , 2012, 133, 133-141.		12
329	Treatment options for acute depression in bipolar disorder. Bipolar Disorders, 2012, 14, 37-50.	1.9	42

#	Article	IF	CITATIONS
330	Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a metaâ€analysis. Bipolar Disorders, 2012, 14, 146-150.	1.9	172
331	Bipolar disorder type II revisited. Bipolar Disorders, 2012, 14, 474-477.	1.9	23
332	Polypharmacy in Psychiatry Practice, Volume II. , 2013, , .		2
333	Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disorders, 2013, 15, 594-621.	1.9	40
334	Behavioral Neurobiology of Depression and Its Treatment. Current Topics in Behavioral Neurosciences, 2013, , .	1.7	4
335	Chemotherapy in Psychiatry., 2013, , .		144
336	The Presentation, Recognition and Management of Bipolar Depression in Primary Care. Journal of General Internal Medicine, 2013, 28, 1648-1656.	2.6	17
337	Guideline for treatment of bipolar disorder by the <scp>J</scp> apanese <scp>S</scp> ociety of <scp>M</scp> ood <scp>D</scp> isorders, 2012. Psychiatry and Clinical Neurosciences, 2013, 67, 285-300.	1.8	59
339	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
340	Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis. CNS Drugs, 2013, 27, 515-529.	5.9	82
341	Monitoring lithium therapy: the impact of a quality improvement programme in the UK. Bipolar Disorders, 2013, 15, 865-875.	1.9	29
342	Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service. BMC Psychiatry, 2013, 13, 211.	2.6	25
343	Comparing Treatment Outcomes of Bipolar Patients Between Psychiatry Residents and Attending Physicians. Academic Psychiatry, 2013, 37, 329.	0.9	0
344	Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. Bipolar Disorders, 2013, 15, 575-583.	1.9	30
345	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. Expert Review of Neurotherapeutics, 2013, 13, 751-754.	2.8	3
346	Hypomania spectrum disorders from adolescence to adulthood: A 15-year follow-up of a community sample. Journal of Affective Disorders, 2013, 145, 190-199.	4.1	18
348	Taiwan consensus of pharmacological treatment for bipolar disorder. Journal of the Chinese Medical Association, 2013, 76, 547-556.	1.4	24
349	A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression. Journal of Affective Disorders, 2013, 144, 176-178.	4.1	5

#	Article	IF	CITATIONS
350	Predictors of later bipolar disorder in patients with subthreshold symptoms. Journal of Affective Disorders, 2013, 144, 129-133.	4.1	24
351	Antidepressants from a public health perspective: reâ€examining effectiveness, suicide, and carcinogenicity. Acta Psychiatrica Scandinavica, 2013, 127, 89-93.	4.5	11
352	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
353	Evidenceâ€based treatment strategies for treatmentâ€resistant bipolar depression: a systematic review. Bipolar Disorders, 2013, 15, 61-69.	1.9	76
354	Treatment of bipolar depression. CNS Spectrums, 2013, 18, 177-187.	1.2	6
355	Overview of antidepressant treatment of bipolar depression. International Journal of Neuropsychopharmacology, 2013, 16, 1673-1685.	2.1	70
356	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry, 2013, 14, 154-219.	2.6	344
357	Treatment of bipolar disorder. Lancet, The, 2013, 381, 1672-1682.	13.7	614
358	Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 207-214.	3.3	4
359	Distinguishing between Unipolar Depression and Bipolar Depression: Current and Future Clinical and Neuroimaging Perspectives. Biological Psychiatry, 2013, 73, 111-118.	1.3	207
360	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	4.0	19
361	Mood-Stabilizing Agents. , 2013, , 89-154.		1
362	A Placebo-Controlled Trial of Acetyl-L-Carnitine and \hat{l} ±-Lipoic Acid in the Treatment of Bipolar Depression. Journal of Clinical Psychopharmacology, 2013, 33, 627-635.	1.4	69
363	Long-Term Naturalistic Follow-Up of Patients With Bipolar Depression and Mixed State Treated With Electroconvulsive Therapy. Journal of ECT, 2013, 29, 179-188.	0.6	19
364	A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectrums, 2013, 18, 199-208.	1.2	17
365	Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. Journal of Psychopharmacology, 2013, 27, 894-902.	4.0	24
366	Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression Findings. JAMA Psychiatry, 2013, 70, 490.	11.0	738
367	Should the term  antipsychotic' be changed to  multidimensional stabiliser' in bipolar disorder? Towards a new denomination for  atypical antipsychotics'. Australian and New Zealand Journal of Psychiatry, 2013, 47, 707-709.	2.3	7

#	Article	IF	Citations
368	Different Neural Responses to a Moral Valence Decision Task in Unipolar and Bipolar Depression. , 2013, 2013, 1-10.		8
369	Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatrica Scandinavica, 2013, 127, 355-364.	4.5	59
373	Effectiveness and Mood Conversion Rate of Short-Term Fluoxetine Monotherapy in Patients With Rapid Cycling Bipolar II Depression Versus Patients With Nonrapid Cycling Bipolar II Depression. Journal of Clinical Psychopharmacology, 2013, 33, 420-424.	1.4	10
374	Therapy of No-Type I Bipolar Spectrum Disorders: A Systematic Review. Current Psychiatry Reviews, 2013, 9, 41-50.	0.9	1
375	New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania. Neuropsychiatric Disease and Treatment, 2013, 9, 753.	2.2	5
376	Extreme Attributions Predict the Course of Bipolar Depression. Journal of Clinical Psychiatry, 2013, 74, 249-255.	2.2	21
379	Pharmacologic and somatic treatments for bipolar depression., 0,, 86-103.		0
380	A Neurobiological Hypothesis of Treatment-Resistant Depression ââ,¬â€œ Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy. Frontiers in Behavioral Neuroscience, 2014, 8, 189.	2.0	66
381	Impact of living with bipolar patients: Making sense of caregivers' burden. World Journal of Psychiatry, 2014, 4, 1.	2.7	55
382	Balancing benefits and harms of treatments for acute bipolar depression. Journal of Affective Disorders, 2014, 169, S24-S33.	4.1	41
383	Psychopharmacology of Bipolar II Depression and Bipolar Depression with Mixed Features. Focus (American Psychiatric Publishing), 2014, 12, 136-145.	0.8	1
384	Bayesian prognostic model for genomic discovery in bipolar disorder. , 2014, , .		1
385	Comorbidity of Social Anxiety Disorder and Attention Deficit Hyperactivity Disorder. Current Approaches in Psychiatry, 2014, 6, 10.	0.4	1
386	Treatment of Pediatric Bipolar Disorder. Current Approaches in Psychiatry, 2014, 6, 1.	0.4	0
387	Polypharmacy and bipolar disorder: what's personality got to do with it?. International Journal of Neuropsychopharmacology, 2014, 17, 1053-1061.	2.1	34
388	The Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations. Pharmacopsychiatry, 2014, 47, 53-59.	3.3	22
389	Treatment of Bipolar Disorder. Focus (American Psychiatric Publishing), 2014, 12, 205-216.	0.8	2
390	Pharmacological treatment of bipolar depression. Advances in Psychiatric Treatment, 2014, 20, 193-201.	0.5	11

#	Article	IF	CITATIONS
391	Differential diagnosis of bipolar disorder and major depressive disorder. Journal of Affective Disorders, 2014, 169, S12-S16.	4.1	153
392	Antidepressants in Bipolar I Disorder: Never as Monotherapy. American Journal of Psychiatry, 2014, 171, 1023-1026.	7.2	35
393	Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of Affective Disorders, 2014, 169, S17-S23.	4.1	29
394	Treatment of bipolar depression: making sensible decisions. CNS Spectrums, 2014, 19, 1-12.	1.2	13
395	A novel cognitive behaviour therapy for bipolar disorders (Think Effectively About Mood Swings or) Tj ETQq0 0 () rgBT/Ove	erlock 10 Tf 5
396	Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. Therapeutic Drug Monitoring, 2014, 36, 730-733.	2.0	23
397	Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy. Journal of ECT, 2014, 30, 165-176.	0.6	98
398	Effect of S-ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression. Journal of ECT, 2014, 30, 176.	0.6	1
399	Family-Focused Therapy Study Raises New Questions. American Journal of Psychiatry, 2014, 171, 603-606.	7.2	2
400	Pharmacotherapy of bipolar disorder: current status and emerging options. Clinical Practice (London, England), 2014, 11, 39-48.	0.1	2
401	The Mood-Stabilizing Effects of Electroconvulsive Therapy. Journal of ECT, 2014, 30, 275-282.	0.6	40
403	Comprehensive Pharmacologic Management of Bipolar Depression. Current Treatment Options in Psychiatry, 2014, 1, 263-277.	1.9	0
404	Revitalizing Psychiatric Therapeutics. Neuropsychopharmacology, 2014, 39, 220-229.	5.4	76
405	A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression. Neuropsychopharmacology, 2014, 39, 2867-2873.	5.4	76
406	Elevated reward-related neural activation as a unique biological marker of bipolar disorder: Assessment and treatment implications. Behaviour Research and Therapy, 2014, 62, 74-87.	3.1	58
407	Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatrica Scandinavica, 2014, 130, 452-469.	4.5	105
408	Staging systems in bipolar disorder: an <scp>I</scp> nternational <scp>S</scp> ociety for <scp>B</scp> ipolar <scp>D</scp> isorders <scp>T</scp> ask <scp>F</scp> orce <scp>R</scp> eport. Acta Psychiatrica Scandinavica, 2014, 130, 354-363.	4.5	175
409	High-dose prazosin for the treatment of post-traumatic stress disorder. Therapeutic Advances in Psychopharmacology, 2014, 4, 43-47.	2.7	48

#	Article	IF	Citations
410	Bipolar disorder and gambling disorder comorbidity: Current evidence and implications for pharmacological treatment. Journal of Affective Disorders, 2014, 167, 285-298.	4.1	34
411	Diagnosis and Management of Bipolar Disorder in Primary Care. Medical Clinics of North America, 2014, 98, 1025-1048.	2.5	9
412	Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Medicine, 2014, 12, 90.	5.5	23
413	Attenuation of mania-like behavior in Na+,K+-ATPase $\hat{l}\pm 3$ mutant mice by prospective therapies for bipolar disorder: Melatonin and exercise. Neuroscience, 2014, 260, 195-204.	2.3	27
414	Rapid Mood-Elevating Effects of Low Field Magnetic Stimulation in Depression. Biological Psychiatry, 2014, 76, 186-193.	1.3	68
415	Medication burden in bipolar disorder: A chart review of patients at psychiatric hospital admission. Psychiatry Research, 2014, 216, 24-30.	3.3	49
416	The vigilance regulation model of affective disorders and ADHD. Neuroscience and Biobehavioral Reviews, 2014, 44, 45-57.	6.1	175
417	Epigenetic mechanisms in mood disorders: Targeting neuroplasticity. Neuroscience, 2014, 264, 112-130.	2.3	54
421	Antidepressants in Type II Versus Type I Bipolar Depression. Journal of Clinical Psychopharmacology, 2015, 35, 605-608.	1.4	16
422	Do Patients at Sites With High RCT Enrollment Propensity Have Better Outcomes?. Medical Care, 2015, 53, 989-995.	2.4	2
423	A Descriptive Analysis of Factors Leading to a 1-Year Remission in Bipolar Disorder. Journal of Psychiatric Practice, 2015, 21, 351-358.	0.7	4
424	Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evidence, 2015, 10, 49.	4.7	21
425	Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules, 2015, 5, 3112-3141.	4.0	87
426	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira De Psiquiatria, 2015, 37, 03-12.	1.7	38
427	Combination Treatment for Anxiety and Mood Disorders. , 2015, , .		0
428	Efficacy and tolerability of treatments for bipolar depression. Journal of Affective Disorders, 2015, 183, 258-262.	4.1	32
429	Are antidepressants mood destabilizers?. Psychiatry Research, 2015, 227, 374-375.	3.3	0
430	Management of bipolar I depression: clinical utility of lurasidone. Therapeutics and Clinical Risk Management, 2015, 11, 75.	2.0	12

#	Article	IF	CITATIONS
431	Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD. Psychiatric Services, 2015, 66, 817-823.	2.0	4
432	Validation of Computerized Adaptive Testing in an Outpatient Nonacademic Setting: The VOCATIONS Trial. Psychiatric Services, 2015, 66, 1091-1096.	2.0	36
433	Suicidal behaviour in bipolar disorder: understanding the role of affective states. Bipolar Disorders, 2015, 17, 24-26.	1.9	6
434	Atypical features and treatment choices in bipolar disorders: a result of the National Bipolar Mania Pathway Survey in China. Neuroscience Bulletin, 2015, 31, 22-30.	2.9	4
435	Psychosocial Approaches to the Treatment of Bipolar Disorder. Focus (American Psychiatric) Tj ETQq0 0 0 rgBT /0	Overlock 1	0
436	Rating Scales in Bipolar Disorder. , 2015, , 105-136.		18
437	Effectiveness Trials in Bipolar Disorders. , 2015, , 23-28.		0
438	Overview of Antidepressant Treatment of Bipolar Depression. Focus (American Psychiatric Publishing), 2015, 13, 102-112.	0.8	2
439	Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. Journal of Affective Disorders, 2015, 185, 31-37.	4.1	48
440	Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. Journal of Psychiatric Research, 2015, 68, 151-156.	3.1	14
441	Predictors of switch from depression to mania in bipolar disorder. Journal of Psychiatric Research, 2015, 66-67, 45-53.	3.1	26
442	Who will benefit from antidepressants in the acute treatment of bipolar depression? A reanalysis of the STEP-BD study by Sachs et al. 2007, using Q-learning. International Journal of Bipolar Disorders, 2015, 3, 7.	2.2	14
443	State-Dependent Differences in Emotion Regulation Between Unmedicated Bipolar Disorder and Major Depressive Disorder. JAMA Psychiatry, 2015, 72, 687.	11.0	77
444	Investigating the mechanism(s) underlying switching between states in bipolar disorder. European Journal of Pharmacology, 2015, 759, 151-162.	3.5	57
445	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disorders, 2015, 17, 86-96.	1.9	19
446	Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 999-1007.e4.	0.5	33
447	Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. American Journal of Health-System Pharmacy, 2015, 72, S156-S161.	1.0	6
448	Variation in response to short-term antidepressant treatment between patients with continuous and non-continuous cycling bipolar disorders. Journal of Affective Disorders, 2015, 174, 126-130.	4.1	4

#	Article	IF	CITATIONS
449	Short-term antidepressant treatment of bipolar depression: Are ISBD recommendations useful in clinical practice?. Journal of Affective Disorders, 2015, 171, 155-160.	4.1	19
450	Time to lack of persistence with pharmacological treatment among patients with current depressive episodes: a natural study with 1-year follow-up. Patient Preference and Adherence, 2016, Volume 10, 2209-2215.	1.8	7
451	Treatment response in relation to subthreshold bipolarity in patients with major depressive disorder receiving antidepressant monotherapy: a post hoc data analysis (KOMDD study). Neuropsychiatric Disease and Treatment, 2016, 12, 1221.	2.2	10
452	Does the "Silver Bullet―Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. Clinical Practice and Epidemiology in Mental Health, 2016, 12, 142-157.	1.2	12
453	Antidepressant Efficacy of the Antipsychotic Quetiapine: Pharmacokinetics, Pharmacodynamics and Clinical Data. Dual Diagnosis (Foster City), $2016, 1, .$	0.0	0
454	Historical Underpinnings of Bipolar Disorder Diagnostic Criteria. Behavioral Sciences (Basel,) Tj ETQq1 1 0.78431	4 rgBT /O	verlgck 10 Ti
455	Rapid versus nonâ€rapid cycling bipolar <scp>II</scp> depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatrica Scandinavica, 2016, 133, 459-469.	4.5	16
456	Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants. Medicine (United States), 2016, 95, e3165.	1.0	8
457	The number of past manic episodes is the best predictor of antidepressant-emergent manic switch in a cohort of bipolar depressed patients. Psychiatry Research, 2016, 240, 288-294.	3.3	7
458	Short-term venlafaxine <i>v.</i> lithium monotherapy for bipolar type II major depressive episodes: Effectiveness and mood conversion rate. British Journal of Psychiatry, 2016, 208, 359-365.	2.8	42
459	MAOIs – does the evidence warrant their resurrection?. Australasian Psychiatry, 2016, 24, 371-373.	0.7	16
460	Clinical Potential of Neurosteroids for CNS Disorders. Trends in Pharmacological Sciences, 2016, 37, 543-561.	8.7	145
461	Single-dose infusion ketamine and non-ketamine <i>N</i> -methyl- <scp>d</scp> -aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 2016, 46, 1459-1472.	4.5	292
462	Bipolar depression. International Journal of Psychiatry in Medicine, 2016, 51, 145-159.	1.8	5
463	Affective instability and the course of bipolar depression: Results from the STEP-BD randomised controlled trial of psychosocial treatment. British Journal of Psychiatry, 2016, 208, 352-358.	2.8	21
464	The Need for Quality Improvement in Behavioral Health. , 2016, , 33-54.		3
465	A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD. Journal of Affective Disorders, 2016, 203, 152-157.	4.1	9
466	Familyâ€Focused Therapy for Bipolar Disorder: Reflections on 30ÂYears of Research. Family Process, 2016, 55, 483-499.	2.6	167

#	Article	IF	CITATIONS
467	Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry,the, 2016, 3, 1138-1146.	7.4	109
468	Adjunctive antidepressants in bipolar depression. Lancet Psychiatry, the, 2016, 3, 1095-1096.	7.4	10
469	Early report on brain arousal regulation in manic vs depressive episodes in bipolar disorder. Bipolar Disorders, 2016, 18, 502-510.	1.9	25
470	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. International Journal of Neuropsychopharmacology, 2016, 20, pyw100.	2.1	77
471	Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression. Contemporary Clinical Trials, 2016, 51, 65-71.	1.8	18
472	Serotonergic dysfunction in bipolar disorder. , 0, , 43-48.		0
474	Adjunctive Behavioral Activation for the Treatment of Bipolar Depression. Journal of Psychiatric Practice, 2016, 22, 149-158.	0.7	11
475	Quality Improvement in Behavioral Health. , 2016, , .		1
476	Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Annals of General Psychiatry, 2016, 15, 9.	2.7	20
477	Psychopharmacology in Primary Care Settings. Primary Care - Clinics in Office Practice, 2016, 43, 327-340.	1.6	3
478	Childhood trauma and treatment outcome in bipolar disorder. Journal of Trauma and Dissociation, 2016, 17, 397-409.	1.9	54
479	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2016, 30, 495-553.	4.0	755
480	Treating Depression 2016. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 179-179.	0.5	0
481	Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Comprehensive Psychiatry, 2016, 66, 146-156.	3.1	25
482	Discriminating Between Bipolar Disorder and Major Depressive Disorder. Psychiatric Clinics of North America, 2016, 39, 1-10.	1.3	44
483	Reply to letter to the editor. Journal of Affective Disorders, 2016, 190, 891-892.	4.1	0
484	The management of bipolar disorder. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 175-179.	0.5	5
486	Les antidépresseurs ont-ils encore un intérêt dans la dépression bipolaire�. Annales Medico-Psychologiques, 2016, 174, 70-76.	0.4	0

#	Article	IF	CITATIONS
487	Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial. British Journal of Psychiatry, 2016, 208, 78-86.	2.8	64
488	Antidepressant medications and the longitudinal course of bipolar disorder revisited. Journal of Affective Disorders, 2016, 190, 889-890.	4.1	0
489	Animal models of bipolar mania: The past, present and future. Neuroscience, 2016, 321, 163-188.	2.3	100
490	Treatment of Bipolar Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial. Neuropsychopharmacology, 2017, 42, 2593-2601.	5.4	69
491	The preclinical discovery and development of quetiapine for the treatment of mania and depression. Expert Opinion on Drug Discovery, 2017, 12, 525-535.	5.0	9
492	Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolamâ€controlled randomized clinical trial. Bipolar Disorders, 2017, 19, 176-183.	1.9	134
493	A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. Journal of Clinical Psychopharmacology, 2017, 37, 355-358.	1.4	28
494	Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension. CNS Spectrums, 2017, 22, 220-227.	1.2	6
496	The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clinic Proceedings, 2017, 92, 1532-1551.	3.0	55
497	Efficacy and safety of long-term antidepressant treatment for bipolar disorders – A meta-analysis of randomized controlled trials. Journal of Affective Disorders, 2017, 223, 41-48.	4.1	54
498	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. Journal of Psychiatric Research, 2017, 95, 208-212.	3.1	4
499	Clinical Use of Mood Stabilizers With Antidepressants in Asia. Journal of Clinical Psychopharmacology, 2017, 37, 255-259.	1.4	7
500	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Review of Clinical Pharmacology, 2017, 10, 153-166.	3.1	24
501	Detecting Bipolar Depression From Geographic Location Data. IEEE Transactions on Biomedical Engineering, 2017, 64, 1761-1771.	4.2	132
502	Depressive and Bipolar Disorders. , 2017, , 423-439.		0
503	Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. Biochemical and Biophysical Research Communications, 2017, 482, 615-624.	2.1	33
504	What is the role of conventional antidepressants in the treatment of major depressive episodes with Mixed Features Specifier?. CNS Spectrums, 2017, 22, 120-125.	1.2	10
505	Manic switches induced by antidepressants: an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatrica Scandinavica, 2017, 135, 106-116.	4.5	19

#	Article	IF	CITATIONS
506	Combined Treatment With CBT and Psychopharmacology., 2017,, 131-153.		1
507	Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression. International Journal of Molecular Sciences, 2017, 18, 2406.	4.1	16
508	Electroconvulsive Therapy in the Treatment of Mood Disorders: One-Year Follow-up. Noropsikiyatri Arsivi, 2017, 54, 196-201.	0.3	7
509	Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq. Pharmacy Practice, 2017, 15, 979-979.	1.5	2
510	Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report. Clinical Practice and Epidemiology in Mental Health, 2017, 13, 43-48.	1.2	0
511	The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features. Current Neuropharmacology, 2017, 15, 359-371.	2.9	108
512	Glutamatergic Modulators in Depression. Harvard Review of Psychiatry, 2018, 26, 307-319.	2.1	70
513	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders, 2018, 234, 131-138.	4.1	16
514	Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients. Journal of Affective Disorders, 2018, 234, 74-79.	4.1	3
515	<scp>CANMAT</scp> and <scp>ISBD</scp> 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 393-394.	1.9	7
516	Substance use comorbidity in bipolar disorder: A qualitative review of treatment strategies and outcomes. American Journal on Addictions, 2018, 27, 188-201.	1.4	28
517	Novel Therapeutics in Bipolar Disorder. Current Treatment Options in Psychiatry, 2018, 5, 162-181.	1.9	1
518	Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with major depressive disorder, bipolar disorder I, and major depressive with alcohol use disorders. Neuroscience Letters, 2018, 671, 128-132.	2.1	12
519	Adjunctive antidepressants in bipolar depression: A cohort study of six- and twelve-months rehospitalization rates. European Neuropsychopharmacology, 2018, 28, 353-360.	0.7	3
520	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective. Expert Opinion on Drug Discovery, 2018, 13, 221-228.	5.0	12
521	An overview of pharmacotherapy for bipolar I disorder. Expert Opinion on Pharmacotherapy, 2018, 19, 203-222.	1.8	18
522	Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression. JAMA Psychiatry, 2018, 75, 158.	11.0	98
523	Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 2018, 35, 402-410.	4.1	9

#	Article	IF	CITATIONS
524	Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study. Journal of Affective Disorders, 2018, 229, 164-170.	4.1	28
525	Does recent mania affect response to antidepressants in bipolar disorder? A re-analysis of STEP-BD data. Journal of Affective Disorders, 2018, 236, 136-139.	4.1	4
526	Mitochondrial Agents for Bipolar Disorder. International Journal of Neuropsychopharmacology, 2018, 21, 550-569.	2.1	31
527	How obstetric settings can help address gaps in psychiatric care for pregnant and postpartum women with bipolar disorder. Archives of Women's Mental Health, 2018, 21, 543-551.	2.6	12
528	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
529	Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry, 2018, 175, 131-139.	7.2	125
530	Pattern recognition of magnetic resonance imaging-based gray matter volume measurements classifies bipolar disorder and major depressive disorder. Journal of Affective Disorders, 2018, 227, 498-505.	4.1	60
531	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry, 2018, 52, 994-1002.	2.3	3
532	Interpretable Dynamic Treatment Regimes. Journal of the American Statistical Association, 2018, 113, 1541-1549.	3.1	46
533	Antidepressants in bipolar depression: an enduring controversy. International Journal of Bipolar Disorders, 2018, 6, 25.	2.2	62
534	Risk of manic switch with antidepressants use in patients with bipolar disorder in a Nigerian neuropsychiatric hospital. South African Journal of Psychiatry, 2018, 24, 1215.	0.4	3
535	Pharmacological Treatment Strategies for Acute Bipolar Depression. Journal of Korean Neuropsychiatric Association, 2018, 57, 287.	0.5	1
536	Treatment of acute bipolar depression. Tzu Chi Medical Journal, 2018, 30, 141.	1.1	4
537	Modelling mood disorders: An ACE solution?. Bipolar Disorders, 2018, 20, 4-16.	1.9	58
538	Using Neuroimaging to Develop Mood Disorder Diagnostic Biomarkers: A Good Forward Step and Some Considerations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 411-413.	1.5	2
539	The Use of Antidepressants in Bipolar Depression. Handbook of Experimental Pharmacology, 2018, 250, 415-442.	1.8	4
540	Rethinking the Approach for the Treatment of Bipolar Depression. Focus (American Psychiatric) Tj ETQq0 0 0 rgB	T /Overloc	k 10 Tf 50 10
541	Hypomanic switch during vortioxetine treatment: a case report. Journal of Theoretical Social Psychology, 2019, 29, 114-116.	1.9	11

#	ARTICLE	IF	CITATIONS
542	Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opinion on Drug Safety, 2019, 18, 893-913.	2.4	6
543	Effects of inflammation modulation on tryptophan and kynurenine pathway regulation in treatment resistant bipolar depression. Neurology Psychiatry and Brain Research, 2019, 33, 65-72.	2.0	6
544	Evidence-Based Psychotherapies for Bipolar Disorder. Focus (American Psychiatric Publishing), 2019, 17, 238-248.	0.8	20
545	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. Journal of Affective Disorders, 2019, 257, 17-22.	4.1	26
546	The Role of Antidepressants in Managing Bipolar II Disorder. , 2019, , 113-128.		0
547	Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better. Focus (American Psychiatric Publishing), 2019, 17, 218-231.	0.8	6
548	Use of "Lights―for Bipolar Depression. Current Psychiatry Reports, 2019, 21, 45.	4.5	7
549	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. BMJ Open, 2019, 9, e025640.	1.9	5
550	Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 2019, 33, 502-510.	4.0	12
551	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). Journal of Psychiatric Research, 2019, 113, 125-136.	3.1	64
552	Precision Medicine. Annual Review of Statistics and Its Application, 2019, 6, 263-286.	7.0	176
553	Lithium and the Woozle effect. Bipolar Disorders, 2019, 21, 302-308.	1.9	14
554	Prescribing practices of Indian psychiatrists in the treatment of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 458-469.	2.3	10
555	Agmatine as a potential therapeutic intervention in bipolar depression: the preclinical landscape. Expert Opinion on Therapeutic Targets, 2019, 23, 327-339.	3.4	9
556	Mood Stabilisers in the Treatment of Bipolar II Disorder. , 2019, , 129-142.		0
557	Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder. Journal of Affective Disorders, 2019, 246, 836-842.	4.1	4
558	A pilot study of brexpiprazole for bipolar depression. Journal of Affective Disorders, 2019, 249, 315-318.	4.1	25
559	Antidepressants in Bipolar Depression: An Enduring Controversy. Focus (American Psychiatric) Tj ETQq1 1 0.7843	14.rgBT /0.8	Oygrlock 10

#	Article	IF	CITATIONS
560	Evidence-Based Principles for Bipolar Disorder Treatment. Focus (American Psychiatric Publishing), 2019, 17, 272-274.	0.8	0
561	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. Focus (American) Tj ETQq1 1 0.78431	.4.rgBT /C) Verlock 10
562	Statistics Commentary Series. Journal of Clinical Psychopharmacology, 2019, 39, 545-546.	1.4	1
563	Ropinirole Augmentation for Depression. Journal of Clinical Psychopharmacology, 2019, 39, 78-81.	1.4	9
564	Treatment-resistant depression: problematic illness or a problem in our approach?. British Journal of Psychiatry, $2019, 214, 1-3$.	2.8	40
565	Hippocampal functional connectivity-based discrimination between bipolar and major depressive disorders. Psychiatry Research - Neuroimaging, 2019, 284, 53-60.	1.8	49
566	Pharmacological treatment of adult bipolar disorder. Molecular Psychiatry, 2019, 24, 198-217.	7.9	143
567	The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on bipolar depression. Bipolar Disorders, 2020, 22, 472-489.	1.9	13
568	Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and metaâ€analysis. Psychiatry and Clinical Neurosciences, 2020, 74, 247-256.	1.8	20
569	Effects of adjunctive inflammatory modulation on IL- \hat{l}^2 in treatment resistant bipolar depression. Brain, Behavior, and Immunity, 2020, 87, 369-376.	4.1	18
570	Differential core pharmacotherapy in bipolar I versus bipolar II disorder and European versus American patients not in a syndromal episode. International Clinical Psychopharmacology, 2020, 35, 8-18.	1.7	9
571	Food and Drug Administration–Approved Treatments for Acute Bipolar Depression. Journal of Clinical Psychopharmacology, 2020, 40, 334-338.	1.4	6
572	Bipolar depression: a major unsolved challenge. International Journal of Bipolar Disorders, 2020, 8, 1.	2.2	137
573	Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. BMC Psychiatry, 2020, 20, 555.	2.6	16
574	Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996–2015. Journal of Affective Disorders, 2020, 276, 883-889.	4.1	20
575	S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. , 2020, , .		2
576	A Systematic Review and Meta-Analysis of Randomized Sham-Controlled Trials of Repetitive Transcranial Magnetic Stimulation for Bipolar Disorder. Psychiatric Quarterly, 2020, 91, 1225-1247.	2.1	13
577	A retrospective analysis of bipolar depression treated with transcranial magnetic stimulation. Brain and Behavior, 2020, 10, e01805.	2.2	7

#	Article	IF	CITATIONS
578	Drugs to Treat Depression., 2020,, 227-267.		0
579	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq1 I	. 0.784314	1 rgBT /Oved
580	Efficacy and safety of bright light therapy for bipolar depression. Psychiatry and Clinical Neurosciences, 2020, 74, 408-410.	1.8	1
581	<p>Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1459-1472.	2.2	9
582	New Directions in Psychiatry. , 2020, , .		0
583	The Treatment of Bipolar Depression: Current Status and Future Perspectives. Current Behavioral Neuroscience Reports, 2020, 7, 1-14.	1.3	3
584	The Inpatient with Depression. , 2020, , 28-62.		0
585	A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. Journal of Affective Disorders, 2020, 275, 38-43.	4.1	31
586	Discriminating bipolar depression from major depressive disorder with polygenic risk scores. Psychological Medicine, 2020, 51, 1-8.	4.5	12
587	Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. Medicina (Lithuania), 2020, 56, 67.	2.0	17
588	Neurocognitive effects of transcranial direct current stimulation (tDCS) in unipolar and bipolar depression: Findings from an international randomized controlled trial. Depression and Anxiety, 2020, 37, 261-272.	4.1	24
589	Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. Journal of Affective Disorders, 2020, 269, 154-184.	4.1	90
590	Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Molecular Psychiatry, 2021, 26, 168-185.	7.9	36
591	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	4.1	5
592	Examining the relationship between gray matter volume and a continuous measure of bipolarity in unmedicated unipolar and bipolar depression. Journal of Affective Disorders, 2021, 280, 105-113.	4.1	2
593	Electroconvulsive Therapy in Mania: A Review of 80 Years of Clinical Experience. American Journal of Psychiatry, 2021, 178, 229-239.	7.2	33
594	Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. Canadian Journal of Psychiatry, 2021, 66, 274-288.	1.9	16
596	Brain Imaging and the Mechanisms of Antidepressant Action. , 2021, , 248-260.		0

#	Article	IF	CITATIONS
597	Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders. , 2021, , 39-48.		0
598	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder. , 2021, , 236-247.		0
599	Magnetoencephalography Studies in Mood Disorders. , 2021, , 192-205.		0
601	Functional Near-Infrared Spectroscopy Studies in Mood Disorders. , 2021, , 166-174.		O
603	Neuroimaging Studies of Effects of Psychotherapy in Depression. , 2021, , 261-272.		0
604	Bipolar I Mania and Atypical Depression. , 2021, , 93-106.		0
605	Neuroimaging Brain Inflammation in Mood Disorders. , 2021, , 121-134.		0
607	An Overview of Machine Learning Applications in Mood Disorders. , 2021, , 206-218.		O
608	Induced pluripotent stem cells as tools to investigate the neurobiology of bipolar disorder and advance novel therapeutic discovery., 2021, , 155-173.		0
609	How Much Is the Debate Over Antidepressant Efficacy and Safety in Bipolar Depression an Artifact of Study Methodologies?. Journal of Clinical Psychiatry, 2021, 82, .	2.2	1
610	Electrophysiological Biomarkers for Mood Disorders. , 2021, , 175-191.		1
611	Safety and Efficacy of Adjunctive Second-Generation Antidepressant Therapy With A Mood Stabiliser or an Atypical Antipsychotic in Acute Bipolar Depression: Randomised Systematic Review and Meta-Analysis of A Placebo-Controlled Trials. Focus (American Psychiatric Publishing), 2021, 19, 129-137.	0.8	3
612	Neuroanatomical Findings in Bipolar Disorder. , 2021, , 16-27.		0
613	Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. , 2021, , 105-120.		O
614	Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders., 2021,, 83-104.		0
615	Brain Imaging Methods in Mood Disorders. , 2021, , 1-6.		0
616	Boarding of Psychiatric Patients in the Emergency Department. , 2021, , 257-262.		0
617	Effects of Lithium on Brain Structure in Bipolar Disorder. , 2021, , 219-235.		1

#	Article	IF	CITATIONS
618	Prescription patterns in clinically stable patients with bipolar disorder: Findings from the Bipolar Disorder Course and Outcome from India (BiD-CoIN) study. Asian Journal of Psychiatry, 2021, 57, 102549.	2.0	13
619	Advances in the psychopharmacotherapy of bipolar disorder type I. Expert Opinion on Pharmacotherapy, 2021, 22, 1267-1290.	1.8	8
620	A Naturalistic Study of Outcomes for Durable Remission in Patients With Bipolar Disorder. Journal of Psychiatric Practice, 2021, 27, 86-91.	0.7	0
621	Elevated salivary cortisol predicts response to adjunctive immune modulation in treatment-resistant bipolar depression. Journal of Affective Disorders Reports, 2021, 4, 100117.	1.7	2
622	Psychopharmacology and Neurotherapeutics. , 2021, , 342-388.		0
623	Disorders Related to Stress and Trauma. , 2021, , 166-178.		0
624	Neglected but not negligible aspects of antidepressants and their availability in bipolar depression. Brain and Behavior, 2021, 11 , e2308.	2.2	5
625	Feeding and Eating Disorders. , 2021, , 289-317.		0
626	Health Policy and Population Health in Behavioral Health Care in the United States., 2021,, 473-485.		0
627	Psychosocial Interventions., 2021,, 389-414.		0
628	Neurocognitive Disorders. , 2021, , 263-288.		0
629	Introduction to the Patient Interview. , 2021, , 38-69.		0
630	Global Health and Mental Health Care Delivery in Low-Resource Settings. , 2021, , 486-496.		0
633	Child Psychiatry and Neurodevelopmental Disorders., 2021,, 318-328.		0
635	Psychiatry of Gender and Sexuality. , 2021, , 448-472.		0
636	Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry, 2022, 27, 58-72.	7.9	117
637	Obsessive-Compulsive and Related Disorders. , 2021, , 146-165.		0
642	Psychiatric Evaluation in the Medical Setting. , 2021, , 415-447.		0

#	Article	IF	CITATIONS
644	Schizophrenia Spectrum and Other Psychotic Disorders., 2021,, 102-127.		0
645	Clinical Neuroscience., 2021,, 9-37.		0
646	Which patients with bipolar depression receive antidepressant augmentation? Results from an observational multicenter study. CNS Spectrums, $2021, 121$.	1.2	0
647	Neuroimaging Biomarkers in Pediatric Mood Disorders. , 2021, , 28-38.		0
648	Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus. , 2021, , 7-15.		0
649	Functional Connectome in Bipolar Disorder. , 2021, , 59-82.		0
650	Resting-State Functional Connectivity in Unipolar Depression. , 2021, , 49-58.		0
651	Imaging Genetic and Epigenetic Markers in Mood Disorders. , 2021, , 135-150.		0
652	fMRI Neurofeedback as Treatment for Depression. , 2021, , 151-165.		0
653	Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies. International Journal of Bipolar Disorders, 2021, 9, 3.	2.2	29
657	Assessing Childhood Psychopathology and Developmental Disabilities. , 2009, , .		6
661	Course and outcome of bipolar disorder — focusing on depressive aspects. , 2009, , 29-46.		1
662	Evidence Based Combination Therapy for Bipolar Disorder. , 2013, , 159-177.		2
663	Bipolare Störungen (ICD-10 F3). , 2009, , 199-221.		1
665	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. CNS Spectrums, 2022, 27, 315-321.	1.2	7
666	Implementation of evidence-based practices for complex mood disorders in primary care safety net clinics Families, Systems and Health, 2018, 36, 267-280.	0.6	21
667	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. Focus (American Psychiatric Publishing), 2011, 9, 500.	0.8	20
668	Efficacy and safety of antidepressant's use in the treatment of depressive episodes in bipolar disorder – review of research. Psychiatria Polska, 2015, 49, 1223-1239.	0.5	10

#	Article	IF	CITATIONS
669	latrogenia y prevenci \tilde{A}^3 n cuaternaria en salud mental. Revista Espanola De Salud Publica, 2011, 85, 513-525.	0.3	12
670	Ceiling effects in the "Effectiveness of adjunctive antidepressant treatment for bipolar depression" study: was the sky the limit?. Revista Brasileira De Psiquiatria, 2011, 33, 102-103.	1.7	2
671	Acute management of bipolar disorders. Australian Prescriber, 2008, 31, 73-76.	1.0	2
672	The Management of Individuals with Bipolar Disorder. Drugs, 2009, 69, 2063-2101.	10.9	46
673	Bipolar depression: trial-based insights to guide patient care. Dialogues in Clinical Neuroscience, 2008, 10, 181-192.	3.7	11
674	Current issues: women and bipolar disorder. Dialogues in Clinical Neuroscience, 2008, 10, 229-238.	3.7	13
675	Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues in Clinical Neuroscience, 2009, $11,73-80$.	3.7	20
676	Pharmaceutical treatment of acute bipolar depression. F1000 Medicine Reports, 2010, 2, .	2.9	8
677	Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials. Neural Regeneration Research, 2013, 8, 2962-74.	3.0	20
679	Impact of Antidepressant Continuation After Acute Positive or Partial Treatment Response for Bipolar Depression. Journal of Clinical Psychiatry, 2009, 70, 450-457.	2.2	65
680	Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2009, 70, 155-162.	2.2	130
681	Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo. Journal of Clinical Psychiatry, 2009, 70, 1273-1280.	2.2	19
682	A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II). Journal of Clinical Psychiatry, 2010, 71, 163-174.	2.2	250
683	The Neurobiology of the Switch Process in Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 1488-1501.	2.2	179
684	International Consensus Group on Depression Prevention in Bipolar Disorder. Journal of Clinical Psychiatry, 2011, 72, 1295-1310.	2.2	27
685	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 803-810.	2.2	111
686	Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients. Journal of Clinical Psychiatry, 2012, 73, 924-930.	2.2	33
687	Antidepressant Action of Atypical Antipsychotics. Journal of Clinical Psychiatry, 2013, 74, e193-e196.	2.2	2

#	Article	IF	Citations
688	Risk of Suicidal Behavior With Antidepressants in Bipolar and Unipolar Disorders. Journal of Clinical Psychiatry, 2014, 75, 720-727.	2.2	25
689	Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes. Journal of Clinical Psychiatry, 2015, 76, 728-734.	2.2	29
690	The Use of Psychotropic Medication in Patients With Emotionally Unstable Personality Disorder Under the Care of UK Mental Health Services. Journal of Clinical Psychiatry, 2015, 76, e512-e518.	2.2	106
691	Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge. Journal of Clinical Psychiatry, 2015, 76, 738-740.	2.2	6
692	The Clinical Management of Bipolar Disorder. primary care companion for CNS disorders, The, 2011, 13,	0.6	53
693	Review of Evidence for Use of Antidepressants in Bipolar Depression. primary care companion for CNS disorders, The, 2014, 16, .	0.6	12
694	A Critical Appraisal of Treatments for Bipolar Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, 23-29.	0.6	10
695	Easing the Burden of Bipolar Disorder: From Urgent Situations to Remission. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 391-402.	0.6	1
696	Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian Journal of Psychiatry, 2016, 58, 259.	0.7	9
697	Antidepressants triggering suicidal ideation: An area of concern. Indian Journal of Pharmacology, 2016, 48, 733.	0.7	1
698	Kefir protective effects against nicotine cessation-induced anxiety and cognition impairments in rats. Advanced Biomedical Research, 2014, 3, 251.	0.5	21
699	Pharmacological Treatment of Refractory Bipolar Disorder: What Does the Evidence Say?. Journal of Depression & Anxiety, 2013, 02, .	0.1	3
700	Psychopharmacological Treatment Status in Outpatients with Bipolar Disorder: A Clinical Survey in Germany. Psychiatry Investigation, 2010, 7, 155.	1.6	9
701	Lamotrigine augmentation for the treatment-resistant mood disorder. Clinical Neuropsychopharmacology and Therapeutics, 2010, 1, 35-42.	0.3	7
702	Treatment-emergent hypomania possibly associated with over-the-counter supplements. Mental Health Clinician, 2017, 7, 160-163.	1.0	3
703	Bipolare Störungen (ICD-10 F3). , 2007, , 179-199.		0
705	Promising avenues of therapeutics for bipolar illness. Dialogues in Clinical Neuroscience, 2008, 10, 193-201.	3.7	6
706	CALM. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 485-486.	0.6	1

#	Article	IF	Citations
707	Polypharmazie in der Behandlung bipolarer Störungen. , 2009, , 95-117.		0
708	Pharmacological treatment of acute bipolar depression. , 2009, , 147-158.		0
709	Non-pharmacological somatic treatments for bipolar depression. , 2009, , 179-190.		0
710	Potential novel treatments for bipolar depression. , 2009, , 191-209.		O
712	Kombinationen von Psychopharmaka. , 2010, , 425-449.		0
715	Comparing the effectiveness of mood stabilizers and antidepressants for bipolar depression treatment: a retrospective chart review. Dusunen Adam, 2010, , 115-120.	0.2	1
716	We Need to Keep Learning from One Another. Psychiatric Annals, 2010, 40, 425-426.	0.1	0
717	Treatment of Bipolar Depression. , 2011, , 197-237.		3
718	ã†ã♥—…ã®è™æ−ã•æ²»ç™,. An Official Journal of the Japan Primary Care Association, 2011, 34, 351-354.	0.1	0
720	Treatment Strategies for Bipolar Disorder. primary care companion for CNS disorders, The, 2011, 13, .	0.6	0
721	In Bipolar Disorder Beyond 10 Weeks of Treatment, the TermAntidepressantsIs a Misnomer. Journal of Clinical Psychiatry, 2011, 72, 871.	2.2	0
722	This Issue: The Conundrum of Bipolar Depression. Psychiatric Annals, 2011, 41, 333-335.	0.1	0
723	Medikamente zur Behandlung bipolarer affektiver Störungen., 2012,, 629-657.		1
724	Anxiety and Depression. , 2012, , 1060-1077.		2
726	Neurochemical and Metabolic Imaging in Bipolar Disorder., 2012,, 79-102.		2
727	Overview of Management Options. , 2013, , 73-94.		0
728	Characteristics of Hispanic Women Screened for Postpartum Depression., 2014,, 1-13.		0
730	Medications Used in Bipolar Depression, Mixed States, and Rapid Cycling., 2013, , 213-222.		O

#	Article	IF	CITATIONS
731	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage. , 2014, , 1-91.		0
732	Bipolar Disorders. , 2014, , 223-251.		0
733	Innovation in the Treatment of Bipolar Depression. Journal of Clinical Psychiatry, 2014, 75, e1185-e1185.	2.2	0
734	Depressive and Bipolar Disorders. , 2015, , 1-17.		O
735	Bipolare affektive Störungen. , 2015, , 1-36.		0
736	Chapter 29. Psychiatry. , 2015, , .		0
737	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage., 2015,, e1-e96.		0
738	A 30-Year-Old Woman Who Has Difficulty Getting Out of Bed. , 2015, , 668-670.		O
739	Depressive and Bipolar Disorders. , 2015, , 1-17.		O
740	Clinical Applicability of Results from Drug Trials in Bipolar Disorder – An Attempt to Shed Light on a Complex Issue. , 2015, , 137-165.		1
741	Treatment-resistant mood disorders. Revista De Psiquiatria Clinica, 2015, 42, 81-82.	0.6	O
742	Behandlung bipolarer StĶrungen. , 2016, , 85-113.		1
743	Potential Novel Treatments in Bipolar Depression. Milestones in Drug Therapy, 2016, , 259-285.	0.1	0
744	Non-pharmacological Somatic Treatments for Bipolar Depression. Milestones in Drug Therapy, 2016, , 243-258.	0.1	O
745	Course and Outcome of Bipolar Disorder: Focus on Depressive Aspects. Milestones in Drug Therapy, 2016, , 33-51.	0.1	0
746	Perils of Pragmatic Psychiatry: How We Can Do Better. Psychiatry Depression & Anxiety, 2016, 2, 1-1.	0.1	0
747	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. , 2017, , 1-111.		0
748	Bipolare affektive Störungen. , 2017, , 1819-1854.		1

#	ARTICLE	IF	CITATIONS
749	Diagnosing and treating bipolar disorder in primary care. Cleveland Clinic Journal of Medicine, 2018, 85, 601-608.	1.3	O
750	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
751	Mood Stabilizers., 2019,,.		0
752	Augmentation Strategies for Treatment-Resistant Disorders. , 2019, , .		0
753	Mood Stabilizers., 2019,,.		0
754	Augmentation Strategies for Treatment-Resistant Disorders. , 2019, , .		0
755	Determining Patient Candidacy for Antidepressant Use in Bipolar Disorder. Psychiatric Annals, 2019, 49, 386-391.	0.1	2
756	Bipolar Disorders. , 2021, , 261-296.		0
757	Affective Disorders., 2021,,.		0
761	Bipolar Disorder: A Review. , 0, , .		0
762	Unmet Needs in Psychiatry: Bipolar Depression. , 2020, , 39-82.		2
763	Comparison of Plasma Levels of Tryptophan Metabolites between Healthy People and Patients of Bipolar Depression at Various Age and Gender. Journal of Biomedical Science and Engineering, 2020, 13, 120-129.	0.4	2
764	Comparative efficacy of mitochondrial agents for bipolar disorder during depressive episodes: a network meta-analysis using frequentist and Bayesian approaches. Psychopharmacology, 2021, 238, 3347-3356.	3.1	3
765	Is the Prescription of Antidepressants for Bipolar Depression Justified from the Point of View of Evidence-Based Medicine?. Psychiatry, 2020, 18, 51-60.	0.7	0
766	Medication Treatment of Bipolar Disorder in Developmentally Disabled Children and Adolescents., 2009,, 253-285.		0
767	Antidepressiva. , 2008, , 515-553.		0
768	Affektive Störungen., 2008,, 873-909.		0
770	The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks. Journal of Psychiatry and Neuroscience, 2007, 32, 232-3.	2.4	0

#	Article	IF	CITATIONS
771	Quetiapine monotherapy for bipolar depression. Neuropsychiatric Disease and Treatment, 2008, 4, 11-21.	2.2	16
772	What is the best treatment for bipolar depression?. Journal of Psychiatry and Neuroscience, 2008, 33, 487-8.	2.4	3
773	Bipolar-I depression outpatient treatment quality and costs in usual care practice. Psychopharmacology Bulletin, 2008, 41, 24-39.	0.0	5
774	Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences?. P and T, 2009, 34, 355-78.	0.9	7
775	Use of antidepressants: expansion beyond depression and anxiety. Psychiatry, 2007, 4, 25-8.	0.3	8
776	Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?. Psychopharmacology Bulletin, 2009, 42, 64-74.	0.0	6
777	Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. American Health and Drug Benefits, 2014, 7, 489-99.	0.5	41
779	Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial. Psychopharmacology Bulletin, 2011, 44, 73-84.	0.0	1
780	The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin, 2018, 48, 64-153.	0.0	1
781	What to Do When Your Depressed Patient Develops Mania. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 26S-33S.	0.6	0
782	Effect of medication therapy combined with transcranial direct current stimulation on depression and response inhibition of patients with bipolar disorder type I: a clinical trial. BMC Psychiatry, 2021, 21, 579.	2.6	7
783	Treating bipolar disorder with rapid cycles: About a case. L'Encephale, 2021, , .	0.9	1
785	Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. European Neuropsychopharmacology, 2022, 54, 100-115.	0.7	43
786	Estimation and Optimization of Composite Outcomes. Journal of Machine Learning Research, 2021, 22, .	62.4	0
787	Neurochemical and metabolic imaging in bipolar disorder., 2022,, 81-105.		0
788	Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Research, 2022, 311, 114468.	3.3	6
790	Antidepressant Treatment and Manic Switch in Bipolar I Disorder: A Clinical and Molecular Genetic Study. Journal of Personalized Medicine, 2022, 12, 615.	2.5	7
792	Pharmacological treatment of bipolar depression. , 0, , 24-32.		0

#	Article	IF	Citations
793	The future at the sleep–psychiatry interface. , 0, , 387-397.		0
794	The inpatient with depression. , 0, , 21-49.		0
795	Is cognitive behaviour therapy applicable to individuals diagnosed with bipolar depression or suboptimal mood stabilizer treatment: a secondary analysis of a large pragmatic effectiveness trial. International Journal of Bipolar Disorders, 2022, 10, 13.	2.2	1
796	Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review. Journal of Psychopharmacology, 2022, 36, 521-530.	4.0	7
797	Characterizing the longitudinal course of symptoms and functioning in bipolar disorder. Psychological Medicine, 2024, 54, 79-89.	4.5	6
799	Degree of exposure to psychotropic medications and mortality in people with bipolar disorder. Acta Psychiatrica Scandinavica, 2023, 147, 186-197.	4.5	1
800	Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary. Clinical Psychopharmacology and Neuroscience, 2022, 20, 747-761.	2.0	5
801	"A sense of the bigger picture:―A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PLoS ONE, 2022, 17, e0279073.	2.5	4
802	Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar ⟨scp⟩treatmentâ€resistant⟨/scp⟩ depression. Bipolar Disorders, 2023, 25, 233-244.	1.9	23
804	Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines. Clinical Psychopharmacology and Neuroscience, 2023, 21, 32-48.	2.0	4
806	Diagnosis and management of bipolar disorders. BMJ, The, 0, , e073591.	6.0	8
807	Perinatal Depression Treatment Guidelines for Obstetric Providers. Obstetrics and Gynecology Clinics of North America, 2023, 50, 589-607.	1.9	1
808	Medications for Bipolar Disorder. , 2023, , 1-31.		0
809	Revisiting the association between treatment with antidepressants and mania: A nationwide withinâ€individual study of 3554 patients with bipolar disorder. Bipolar Disorders, 0, , .	1.9	1
810	A systematic review of manic/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs. European Neuropsychopharmacology, 2023, 73, 1-15.	0.7	4
812	Patterns of pharmacotherapy for bipolar disorder: A <scp>GBC</scp> survey. Bipolar Disorders, 2024, 26, 22-32.	1.9	7
813	The impact of body mass index on the clinical features of bipolar disorder: A <scp>STEPâ€BD</scp> study. Bipolar Disorders, O, , .	1.9	0
814	Multiâ€trial, aggregated, <scp>individual participant</scp> data megaâ€analysis of shortâ€term antidepressant versus mood stabilizer monotherapy of bipolar type <scp>ll</scp> major depressive episode. Bipolar Disorders, 0, , .	1.9	1

#	Article	IF	CITATIONS
815	Adjunctive antidepressants for the treatment of bipolar depression: An updated meta-analysis of randomized clinical trials. Asian Journal of Psychiatry, 2024, 91, 103839.	2.0	0
819	Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice. International Journal of Bipolar Disorders, 2024, 12, .	2.2	0
821	Antidepressant monotherapy in treatmentâ€refractory bipolar <scp>II</scp> depression. Bipolar Disorders, 0, , .	1.9	0
822	Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study. Drugs and Therapy Perspectives, 2024, 40, 109-114.	0.6	O